MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

COVID-19 Tests: Nasopharyngeal Swab vs Saliva Collected With Salivette® Cortisol for Viral RNA Sampling for RT-qPCR

Not Applicable
Completed
Conditions
Covid-19
Interventions
Diagnostic Test: Sampling of SARS-CoV-2 RNA from nasopharyngeal swab specimen or saliva collected via Salivette Cortisol
First Posted Date
2020-10-23
Last Posted Date
2021-07-26
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
151
Registration Number
NCT04599959
Locations
🇲🇽

Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico, Mexico

A Study in Healthy People to Test Whether BI 730357 Affects How 4 Other Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Taken up in the Body

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Lenoxin®
Drug: MetfoLiquid GeriaSan®
First Posted Date
2020-10-19
Last Posted Date
2023-09-06
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
15
Registration Number
NCT04590937
Locations
🇩🇪

Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study in Healthy Men to Test How BI 1358894 is Taken up and Handled by the Body

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: [14C]-radiolabelled BI 1358894
First Posted Date
2020-09-28
Last Posted Date
2025-02-27
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
15
Registration Number
NCT04567316
Locations
🇳🇱

ICON, Groningen, Netherlands

A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder

Phase 2
Completed
Conditions
Borderline Personality Disorder
Interventions
Drug: Placebo
First Posted Date
2020-09-28
Last Posted Date
2024-01-30
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
390
Registration Number
NCT04566601
Locations
🇺🇸

McLean Hospital, Belmont, Massachusetts, United States

🇦🇷

Fundación para el Estudio y Tratamiento de las Enfermedades Mentales (FETEM), Caba, Argentina

🇦🇷

Instituto Médico DAMIC S.R.L., Cordoba, Argentina

and more 64 locations

Post-marketing Surveillance of Ofev Capsules in Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype in Japan

Completed
Conditions
Lung Diseases, Interstitial
Interventions
First Posted Date
2020-09-23
Last Posted Date
2025-02-28
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
425
Registration Number
NCT04559581
Locations
🇯🇵

Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan

A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung

Completed
Conditions
Squamous Non-small Cell Lung Cancer
Interventions
Drug: Second line (2L) afatinib
Drug: Second line chemotherapy
First Posted Date
2020-09-17
Last Posted Date
2022-01-11
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
200
Registration Number
NCT04552535
Locations
🇺🇸

Cardinal Health Specialty Solutions, Dublin, Ohio, United States

A Study in Healthy Japanese Men to Test How Different Doses of BI 894416 Are Tolerated

Phase 1
Terminated
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2020-09-07
Last Posted Date
2023-08-16
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
8
Registration Number
NCT04540874
Locations
🇯🇵

Clinical Research Hospital Tokyo, Tokyo, Shinjuku-ku, Japan

A Study in Healthy Men and Women Who Are Either Between 18 - 45 Years or Between 65 - 80 Years to Test How Different Doses of BI 474121 Are Tolerated

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2020-09-03
Last Posted Date
2024-03-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
70
Registration Number
NCT04537897
Locations
🇩🇪

CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

ReAHEAD: A Study to Find Out Whether Education Improves Adherence to Dabigatran in People With Atrial Fibrillation Who Are Younger Than 75 Years

Completed
Conditions
Atrial Fibrillation
Interventions
First Posted Date
2020-08-31
Last Posted Date
2025-05-15
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
898
Registration Number
NCT04532528
Locations
🇨🇳

Buddhist Tzu Chi General Hospital, Hualien, Taiwan

🇨🇳

National Taiwan University Hospital-Hsin-Chu Branch, Hsinchu, Taiwan

🇨🇳

Pingtung Christian Hospital, Pingtung, Taiwan

and more 20 locations

A Study to Test How Well Empagliflozin Works in Japanese People With Type 2 Diabetes Who Are Older Than 65 Years

Phase 4
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: Placebo
First Posted Date
2020-08-28
Last Posted Date
2024-05-02
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
129
Registration Number
NCT04531462
Locations
🇯🇵

North Alps Medical Center Azumi Hospital, Nagano, Kitaazumi-gun, Japan

🇯🇵

Shinagawa East one Medical Clinic, Tokyo, Minato-ku, Japan

🇯🇵

Chubu Rosai Hospital, Aichi, Nagoya, Japan

and more 15 locations
© Copyright 2025. All Rights Reserved by MedPath